Consolidative Use Of Radiotherapy To Block (Curb2) Oligoprogression In Patients With Metastatic Non-Small-Cell Lung Cancer - A Randomized Phase 3 Trial (BR.38)
Objective
Primary: To evaluate if the addition of SBRT to extra-cranial oligoprogressive metastatic disease can prolong progression-free survival (PFS) and/or overall survival (OS) compared to SOC systemic therapy alone in participants with oligoprogressive NSCLC.
Secondary: To evaluate both treatment strategies with respect to: - Safety and tolerability (using CTCAE Version 5.0) - Participant-reported adverse events (using PRO-CTCAE questionnaire) - Participant-reported quality of life (using EORTC-QLQ-C30 and QLQ-LC13 questionnaires) - Cost-effectiveness (using EQ-5D-5L questionnaire; CCTG Canadian sites only)
